Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04468230 · ClinicalTrials.gov registry record · Phase 2
Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04468230 is a Phase 2 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 4 participants.
The verdict
NCT04468230, a Phase 2 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Assess the efficacy of short-term nicotine transdermal patch administration for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) in cancer stable patients or patients in remission.
Interventions
- DRUG Nicotine Transdermal Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-07-31 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04468230
The ClinicalTrials.gov registry entry for NCT04468230 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nicotine Transdermal Patch is the first listed.
NCT04468230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04468230 about?
NCT04468230 is a clinical study titled "Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy". Assess the efficacy of short-term nicotine transdermal patch administration for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) in cancer stable patients or patients in remission.
What is the current status of trial NCT04468230?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2020-07-31. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT04468230?
The interventions under investigation include: Nicotine Transdermal Patch (DRUG).
Who is sponsoring clinical trial NCT04468230?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.